Loading…

Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial

In a prospective, randomized, parallel study, two regimens of platelet-suppressant therapy (PST)--dipyridamole-aspirin and pentoxifylline-aspirin--were compared with standard oral anticoagulation with warfarin in the prevention of prosthetic heart valve thromboembolism. In the entire group of 254 pa...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 1985-11, Vol.72 (5), p.1059-1063
Main Authors: MOK, C. K, BOEY, J, WANG, R, CHAN, T. K, CHEUNG, K. L, LEE, P. K, CHOW, J, NG, R. P, TSE, T. F
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c406t-dccce87c1e08fd5b894952fc4755c0fe4b07ce39a932dfb7a8c6f85d2cd721cf3
cites
container_end_page 1063
container_issue 5
container_start_page 1059
container_title Circulation (New York, N.Y.)
container_volume 72
creator MOK, C. K
BOEY, J
WANG, R
CHAN, T. K
CHEUNG, K. L
LEE, P. K
CHOW, J
NG, R. P
TSE, T. F
description In a prospective, randomized, parallel study, two regimens of platelet-suppressant therapy (PST)--dipyridamole-aspirin and pentoxifylline-aspirin--were compared with standard oral anticoagulation with warfarin in the prevention of prosthetic heart valve thromboembolism. In the entire group of 254 patients followed for 395.6 patient-years, the thromboembolic rate was significantly less in the warfarin group (warfarin vs dipyridamole-aspirin, p less than .005; warfarin vs pentoxifylline-aspirin, p less than .05). Subgroup analysis disclosed that, in patients with isolated mitral valve replacement, warfarin was superior to both of the PSTs with respect to the prevention of thromboembolism (warfarin vs dipyridamole-aspirin, p = .005; warfarin vs pentoxifylline-aspirin, p less than .05). Furthermore, a significant number of our patients could not tolerate the antiplatelet agents. However, in the rare situation in which repeated significant bleeding occurs despite careful adjustment of the dosage of warfarin, PST may be an acceptable alternate method of thromboembolism prophylaxis.
doi_str_mv 10.1161/01.CIR.72.5.1059
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76372603</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76372603</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-dccce87c1e08fd5b894952fc4755c0fe4b07ce39a932dfb7a8c6f85d2cd721cf3</originalsourceid><addsrcrecordid>eNpFkU1r3DAQhkVpSDdp770UdCi92ZVky7J7K0s_AoFCSelRyNKIqMiWK3mXbP5P_2dmkyU9CDF6n_nQvIS85azmvOMfGa-3Vz9rJWpZcyaHF2TDpWirVjbDS7JhjA2VaoR4RS5K-YNh1yh5Ts6bfhha1m7Iv98me5PDTPeQy65QF5ZDDs5MKUJlyhKOmpkdXWBe013whxjD_F_yKdP1FuiSYY9ESDNNHqNU8HUNlt6CySvdm7gHBHOaxgR4YijTJ2oeyQXsGlDO2CdN4R4ctdgkWBPpmoOJr8mZN7HAm9N9SX59_XKz_V5d__h2tf18XdmWdWvlrLXQK8uB9d7JsR_aQQpvWyWlZR7akSkLzWCGRjg_KtPbzvfSCeuU4NY3l-TDU12c6u8OyqqnUCzEaGZIu6IVrk90rEGQPYEWxy8ZvF5ymEw-aM700RnNuEZntBJa6qMzmPLuVHs3TuCeE05WoP7-pJuCH_e4DBvKM9a3HZopmwe_U50G</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76372603</pqid></control><display><type>article</type><title>Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial</title><source>Free E-Journal (出版社公開部分のみ)</source><creator>MOK, C. K ; BOEY, J ; WANG, R ; CHAN, T. K ; CHEUNG, K. L ; LEE, P. K ; CHOW, J ; NG, R. P ; TSE, T. F</creator><creatorcontrib>MOK, C. K ; BOEY, J ; WANG, R ; CHAN, T. K ; CHEUNG, K. L ; LEE, P. K ; CHOW, J ; NG, R. P ; TSE, T. F</creatorcontrib><description>In a prospective, randomized, parallel study, two regimens of platelet-suppressant therapy (PST)--dipyridamole-aspirin and pentoxifylline-aspirin--were compared with standard oral anticoagulation with warfarin in the prevention of prosthetic heart valve thromboembolism. In the entire group of 254 patients followed for 395.6 patient-years, the thromboembolic rate was significantly less in the warfarin group (warfarin vs dipyridamole-aspirin, p less than .005; warfarin vs pentoxifylline-aspirin, p less than .05). Subgroup analysis disclosed that, in patients with isolated mitral valve replacement, warfarin was superior to both of the PSTs with respect to the prevention of thromboembolism (warfarin vs dipyridamole-aspirin, p = .005; warfarin vs pentoxifylline-aspirin, p less than .05). Furthermore, a significant number of our patients could not tolerate the antiplatelet agents. However, in the rare situation in which repeated significant bleeding occurs despite careful adjustment of the dosage of warfarin, PST may be an acceptable alternate method of thromboembolism prophylaxis.</description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>DOI: 10.1161/01.CIR.72.5.1059</identifier><identifier>PMID: 3899404</identifier><identifier>CODEN: CIRCAZ</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams &amp; Wilkins</publisher><subject>Adult ; Aspirin - therapeutic use ; Biological and medical sciences ; Blood. Blood coagulation. Reticuloendothelial system ; Clinical Trials as Topic ; Dipyridamole - therapeutic use ; Drug Combinations ; Female ; Heart Valve Prosthesis ; Humans ; Male ; Medical sciences ; Middle Aged ; Pentoxifylline - therapeutic use ; Pharmacology. Drug treatments ; Postoperative Complications - drug therapy ; Postoperative Complications - prevention &amp; control ; Prospective Studies ; Random Allocation ; Theobromine - analogs &amp; derivatives ; Thromboembolism - drug therapy ; Thromboembolism - prevention &amp; control ; Warfarin - therapeutic use</subject><ispartof>Circulation (New York, N.Y.), 1985-11, Vol.72 (5), p.1059-1063</ispartof><rights>1986 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406t-dccce87c1e08fd5b894952fc4755c0fe4b07ce39a932dfb7a8c6f85d2cd721cf3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=8460095$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3899404$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MOK, C. K</creatorcontrib><creatorcontrib>BOEY, J</creatorcontrib><creatorcontrib>WANG, R</creatorcontrib><creatorcontrib>CHAN, T. K</creatorcontrib><creatorcontrib>CHEUNG, K. L</creatorcontrib><creatorcontrib>LEE, P. K</creatorcontrib><creatorcontrib>CHOW, J</creatorcontrib><creatorcontrib>NG, R. P</creatorcontrib><creatorcontrib>TSE, T. F</creatorcontrib><title>Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial</title><title>Circulation (New York, N.Y.)</title><addtitle>Circulation</addtitle><description>In a prospective, randomized, parallel study, two regimens of platelet-suppressant therapy (PST)--dipyridamole-aspirin and pentoxifylline-aspirin--were compared with standard oral anticoagulation with warfarin in the prevention of prosthetic heart valve thromboembolism. In the entire group of 254 patients followed for 395.6 patient-years, the thromboembolic rate was significantly less in the warfarin group (warfarin vs dipyridamole-aspirin, p less than .005; warfarin vs pentoxifylline-aspirin, p less than .05). Subgroup analysis disclosed that, in patients with isolated mitral valve replacement, warfarin was superior to both of the PSTs with respect to the prevention of thromboembolism (warfarin vs dipyridamole-aspirin, p = .005; warfarin vs pentoxifylline-aspirin, p less than .05). Furthermore, a significant number of our patients could not tolerate the antiplatelet agents. However, in the rare situation in which repeated significant bleeding occurs despite careful adjustment of the dosage of warfarin, PST may be an acceptable alternate method of thromboembolism prophylaxis.</description><subject>Adult</subject><subject>Aspirin - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Clinical Trials as Topic</subject><subject>Dipyridamole - therapeutic use</subject><subject>Drug Combinations</subject><subject>Female</subject><subject>Heart Valve Prosthesis</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pentoxifylline - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Postoperative Complications - drug therapy</subject><subject>Postoperative Complications - prevention &amp; control</subject><subject>Prospective Studies</subject><subject>Random Allocation</subject><subject>Theobromine - analogs &amp; derivatives</subject><subject>Thromboembolism - drug therapy</subject><subject>Thromboembolism - prevention &amp; control</subject><subject>Warfarin - therapeutic use</subject><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1985</creationdate><recordtype>article</recordtype><recordid>eNpFkU1r3DAQhkVpSDdp770UdCi92ZVky7J7K0s_AoFCSelRyNKIqMiWK3mXbP5P_2dmkyU9CDF6n_nQvIS85azmvOMfGa-3Vz9rJWpZcyaHF2TDpWirVjbDS7JhjA2VaoR4RS5K-YNh1yh5Ts6bfhha1m7Iv98me5PDTPeQy65QF5ZDDs5MKUJlyhKOmpkdXWBe013whxjD_F_yKdP1FuiSYY9ESDNNHqNU8HUNlt6CySvdm7gHBHOaxgR4YijTJ2oeyQXsGlDO2CdN4R4ctdgkWBPpmoOJr8mZN7HAm9N9SX59_XKz_V5d__h2tf18XdmWdWvlrLXQK8uB9d7JsR_aQQpvWyWlZR7akSkLzWCGRjg_KtPbzvfSCeuU4NY3l-TDU12c6u8OyqqnUCzEaGZIu6IVrk90rEGQPYEWxy8ZvF5ymEw-aM700RnNuEZntBJa6qMzmPLuVHs3TuCeE05WoP7-pJuCH_e4DBvKM9a3HZopmwe_U50G</recordid><startdate>198511</startdate><enddate>198511</enddate><creator>MOK, C. K</creator><creator>BOEY, J</creator><creator>WANG, R</creator><creator>CHAN, T. K</creator><creator>CHEUNG, K. L</creator><creator>LEE, P. K</creator><creator>CHOW, J</creator><creator>NG, R. P</creator><creator>TSE, T. F</creator><general>Lippincott Williams &amp; Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198511</creationdate><title>Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial</title><author>MOK, C. K ; BOEY, J ; WANG, R ; CHAN, T. K ; CHEUNG, K. L ; LEE, P. K ; CHOW, J ; NG, R. P ; TSE, T. F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-dccce87c1e08fd5b894952fc4755c0fe4b07ce39a932dfb7a8c6f85d2cd721cf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1985</creationdate><topic>Adult</topic><topic>Aspirin - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Clinical Trials as Topic</topic><topic>Dipyridamole - therapeutic use</topic><topic>Drug Combinations</topic><topic>Female</topic><topic>Heart Valve Prosthesis</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pentoxifylline - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Postoperative Complications - drug therapy</topic><topic>Postoperative Complications - prevention &amp; control</topic><topic>Prospective Studies</topic><topic>Random Allocation</topic><topic>Theobromine - analogs &amp; derivatives</topic><topic>Thromboembolism - drug therapy</topic><topic>Thromboembolism - prevention &amp; control</topic><topic>Warfarin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MOK, C. K</creatorcontrib><creatorcontrib>BOEY, J</creatorcontrib><creatorcontrib>WANG, R</creatorcontrib><creatorcontrib>CHAN, T. K</creatorcontrib><creatorcontrib>CHEUNG, K. L</creatorcontrib><creatorcontrib>LEE, P. K</creatorcontrib><creatorcontrib>CHOW, J</creatorcontrib><creatorcontrib>NG, R. P</creatorcontrib><creatorcontrib>TSE, T. F</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MOK, C. K</au><au>BOEY, J</au><au>WANG, R</au><au>CHAN, T. K</au><au>CHEUNG, K. L</au><au>LEE, P. K</au><au>CHOW, J</au><au>NG, R. P</au><au>TSE, T. F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><addtitle>Circulation</addtitle><date>1985-11</date><risdate>1985</risdate><volume>72</volume><issue>5</issue><spage>1059</spage><epage>1063</epage><pages>1059-1063</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><coden>CIRCAZ</coden><abstract>In a prospective, randomized, parallel study, two regimens of platelet-suppressant therapy (PST)--dipyridamole-aspirin and pentoxifylline-aspirin--were compared with standard oral anticoagulation with warfarin in the prevention of prosthetic heart valve thromboembolism. In the entire group of 254 patients followed for 395.6 patient-years, the thromboembolic rate was significantly less in the warfarin group (warfarin vs dipyridamole-aspirin, p less than .005; warfarin vs pentoxifylline-aspirin, p less than .05). Subgroup analysis disclosed that, in patients with isolated mitral valve replacement, warfarin was superior to both of the PSTs with respect to the prevention of thromboembolism (warfarin vs dipyridamole-aspirin, p = .005; warfarin vs pentoxifylline-aspirin, p less than .05). Furthermore, a significant number of our patients could not tolerate the antiplatelet agents. However, in the rare situation in which repeated significant bleeding occurs despite careful adjustment of the dosage of warfarin, PST may be an acceptable alternate method of thromboembolism prophylaxis.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>3899404</pmid><doi>10.1161/01.CIR.72.5.1059</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0009-7322
ispartof Circulation (New York, N.Y.), 1985-11, Vol.72 (5), p.1059-1063
issn 0009-7322
1524-4539
language eng
recordid cdi_proquest_miscellaneous_76372603
source Free E-Journal (出版社公開部分のみ)
subjects Adult
Aspirin - therapeutic use
Biological and medical sciences
Blood. Blood coagulation. Reticuloendothelial system
Clinical Trials as Topic
Dipyridamole - therapeutic use
Drug Combinations
Female
Heart Valve Prosthesis
Humans
Male
Medical sciences
Middle Aged
Pentoxifylline - therapeutic use
Pharmacology. Drug treatments
Postoperative Complications - drug therapy
Postoperative Complications - prevention & control
Prospective Studies
Random Allocation
Theobromine - analogs & derivatives
Thromboembolism - drug therapy
Thromboembolism - prevention & control
Warfarin - therapeutic use
title Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T01%3A38%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Warfarin%20versus%20dipyridamole-aspirin%20and%20pentoxifylline-aspirin%20for%20the%20prevention%20of%20prosthetic%20heart%20valve%20thromboembolism:%20a%20prospective%20randomized%20clinical%20trial&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=MOK,%20C.%20K&rft.date=1985-11&rft.volume=72&rft.issue=5&rft.spage=1059&rft.epage=1063&rft.pages=1059-1063&rft.issn=0009-7322&rft.eissn=1524-4539&rft.coden=CIRCAZ&rft_id=info:doi/10.1161/01.CIR.72.5.1059&rft_dat=%3Cproquest_cross%3E76372603%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c406t-dccce87c1e08fd5b894952fc4755c0fe4b07ce39a932dfb7a8c6f85d2cd721cf3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=76372603&rft_id=info:pmid/3899404&rfr_iscdi=true